Owens & Minor (NYSE:OMI) Updates FY 2025 Earnings Guidance

Owens & Minor (NYSE:OMI - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.600-1.850 for the period, compared to the consensus estimate of 1.740. The company issued revenue guidance of $10.9 billion-$11.2 billion, compared to the consensus revenue estimate of $11.0 billion.

Owens & Minor Stock Performance

Shares of Owens & Minor stock traded up $0.03 during trading on Friday, reaching $7.02. The company's stock had a trading volume of 1,798,096 shares, compared to its average volume of 1,121,481. The business's fifty day moving average price is $8.13 and its 200-day moving average price is $10.79. Owens & Minor has a one year low of $6.07 and a one year high of $21.02. The firm has a market cap of $542.33 million, a price-to-earnings ratio of -10.80, a price-to-earnings-growth ratio of 0.20 and a beta of 1.38. The company has a debt-to-equity ratio of 2.11, a quick ratio of 0.45 and a current ratio of 1.09.

Owens & Minor (NYSE:OMI - Get Free Report) last issued its quarterly earnings results on Saturday, May 10th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. Owens & Minor had a positive return on equity of 14.60% and a negative net margin of 0.46%. During the same quarter last year, the firm earned $0.19 earnings per share. The company's quarterly revenue was up .7% compared to the same quarter last year. As a group, equities research analysts predict that Owens & Minor will post 1.51 earnings per share for the current year.

Owens & Minor declared that its board has initiated a stock repurchase program on Friday, February 28th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 13.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its stock is undervalued.

Analysts Set New Price Targets

OMI has been the topic of several research reports. Citigroup lowered their price target on Owens & Minor from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Robert W. Baird upped their target price on Owens & Minor from $10.00 to $11.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. JPMorgan Chase & Co. decreased their price target on shares of Owens & Minor from $14.00 to $10.00 and set an "underweight" rating on the stock in a research note on Monday, March 10th. Finally, UBS Group dropped their price objective on shares of Owens & Minor from $25.00 to $13.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $12.50.

Insider Buying and Selling

In related news, major shareholder Coliseum Capital Management, L purchased 1,738,511 shares of Owens & Minor stock in a transaction that occurred on Friday, February 28th. The shares were acquired at an average price of $9.39 per share, for a total transaction of $16,324,618.29. Following the transaction, the insider now directly owns 9,469,698 shares in the company, valued at approximately $88,920,464.22. This represents a 22.49 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders bought 2,718,412 shares of company stock worth $24,495,308 in the last quarter. 3.69% of the stock is owned by corporate insiders.

Owens & Minor Company Profile

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.